1. Development and Use of Human Recombinant 64 Cu-rHCF as a Kidney Glomerulus-Targeted Contrast Agent for Positron Emission Tomography.
- Author
-
Baldelomar EJ, Zhang H, Thorek D, Charlton JR, Walker PD, Wilson LD, Emoto KC, Clavijo Jordan V, Reichert DE, Shoghi K, and Bennett KM
- Subjects
- Humans, Animals, Ferritins chemistry, Ferritins metabolism, Particle Size, Mice, Positron-Emission Tomography, Contrast Media chemistry, Copper Radioisotopes chemistry, Recombinant Proteins chemistry, Materials Testing, Biocompatible Materials chemistry, Biocompatible Materials pharmacology, Kidney Glomerulus metabolism, Kidney Glomerulus diagnostic imaging
- Abstract
In this work, we develop recombinant human cationic ferritin (rHCF) as a contrast agent to detect glomeruli in the kidney using positron emission tomography (PET). We first expressed recombinant human ferritin (rHF) in E. coli and then functionalized and radiolabeled it with Copper-64 (
64 Cu) to form64 Cu-rHCF. Intravenously injected64 Cu-rHCF bound to kidney glomeruli and was detected by PET. A subchronic toxicity study after an intravenous injection of rHCF revealed no significant toxicity. The development of rHCF is an important step toward the potential clinical translation of CF to detect the nephron number in humans.- Published
- 2024
- Full Text
- View/download PDF